We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+4.94%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$6.98B
AUM Growth
+$857M
(+14%)
Cap. Flow
+$784M
Cap. Flow
% of AUM
11.24%
Top 10 Holdings %
Top 10 Hldgs %
16.48%
Holding
878
New
205
Increased
124
Reduced
98
Closed
184
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qorvo
QRVO
|
+$153M |
| 2 |
ASML
ASML
|
+$117M |
| 3 |
Revolution Medicines
RVMD
|
+$58.1M |
| 4 |
Meta Platforms (Facebook)
META
|
+$49.6M |
| 5 |
Intuitive Surgical
ISRG
|
+$48.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teradyne
TER
|
+$132M |
| 2 |
Qualcomm
QCOM
|
+$77.3M |
| 3 |
Abbott
ABT
|
+$69.2M |
| 4 |
Booking.com
BKNG
|
+$67.7M |
| 5 |
KLA
KLAC
|
+$63.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 41.18% |
| 2 | Technology | 29.45% |
| 3 | Communication Services | 6.73% |
| 4 | Industrials | 6.43% |
| 5 | Financials | 4.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OKLO
226
Oklo
OKLO
$7.54B
| $7.88M | 0.11% |
800,000
| – | – |
|
227
Relay Therapeutics
RLAY
$4.26B
| $7.85M | 0.11% |
255,601
| – | – |
|
228
United Therapeutics
UTHR
$22B
| $7.82M | 0.11% |
+36,211
| New | +$7.11M |
|
|
CERE
229
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $7.69M | 0.11% |
237,326
+41,995
| +21% | +$1.48M |
|
230
iHeartMedia
IHRT
$582M
| $7.58M | 0.11% |
+360,453
| New | +$7.63M |
|
231
Dave Inc
DAVE
$5.46B
| $7.5M | 0.11% |
23,438
| – | – |
|
232
Sana Biotechnology
SANA
$946M
| $7.47M | 0.11% |
482,706
+62,839
| +15% | +$1.21M |
|
233
System1
SST
$16.5M
| $7.47M | 0.11% |
75,000
| – | – |
|
234
Allogene Therapeutics
ALLO
$656M
| $7.46M | 0.11% |
500,095
-312,635
| -38% | -$5.52M |
|
|
GCAC
235
DELISTED
Growth Capital Acquisition Corp. Class A Common Stock
GCAC
| $7.45M | 0.11% |
750,000
| – | – |
|
236
Infosys
INFY
$51B
| $7.44M | 0.11% |
294,075
-235,819
| -45% | -$5.48M |
|
237
Samsara
IOT
$22.5B
| $7.42M | 0.11% |
+263,819
| New | +$6.87M |
|
238
AlTi Global
ALTI
$412M
| $7.41M | 0.11% |
749,999
+300,000
| +67% | +$2.97M |
|
239
Seer Inc
SEER
$122M
| $7.39M | 0.11% |
324,180
+95,365
| +42% | +$2.75M |
|
|
MRUS
240
DELISTED
Merus
MRUS
| $7.37M | 0.11% |
+231,737
| New | +$6.55M |
|
241
Cullinan Oncology
CGEM
$1.08B
| $7.33M | 0.11% |
475,058
| – | – |
|
|
RACB
242
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $7.29M | 0.1% |
750,000
| – | – |
|
|
AUS
243
DELISTED
Austerlitz Acquisition Corporation I
AUS
| $7.28M | 0.1% |
750,000
| – | – |
|
|
ANSS
244
DELISTED
Ansys
ANSS
| $7.28M | 0.1% |
+18,146
| New | +$6.97M |
|
245
Workday
WDAY
$42.3B
| $6.97M | 0.1% |
25,508
-74,684
| -75% | -$20.7M |
|
246
Nerdy
NRDY
$107M
| $6.91M | 0.1% |
1,536,171
-50,155
| -3% | -$358K |
|
247
PMV Pharmaceuticals
PMVP
$62.4M
| $6.9M | 0.1% |
298,610
-108,755
| -27% | -$2.63M |
|
248
Syndax Pharmaceuticals
SNDX
$1.69B
| $6.79M | 0.1% |
310,377
-270,931
| -47% | -$5.01M |
|
|
BPMC
249
DELISTED
Blueprint Medicines
BPMC
| $6.65M | 0.1% |
62,055
-109,980
| -64% | -$11.5M |
|
250
Nu Holdings
NU
$69.2B
| $6.64M | 0.1% |
+708,311
| New | +$6.95M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q4 2021 Portfolio in Review
As of Q4 2021, Woodline Partners held 878 positions worth $6.98B, up 14% from $6.12B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Woodline Partners deployed $784M of net new capital in Q4 2021, opening 205 new positions and adding to 124 existing holdings. Its largest new stake was Qorvo: 963,210 shares worth $151M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 46% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was KLA, an estimated $63.2M trimmed.
- Woodline Partners's largest Q4 2021 buy was Qorvo: 963,210 shares worth $151M.
- Woodline Partners added most to ASML in Q4 2021, an estimated $117M increase.
- Woodline Partners's biggest Q4 2021 reduction was KLA, cutting an estimated $63.2M.
- Woodline Partners fully exited Teradyne in Q4 2021, selling an estimated $132M.
- Woodline Partners's ten largest holdings make up 16% of its $6.98B portfolio in Q4 2021.
- Woodline Partners opened 205 new positions and closed 184 in Q4 2021.
- Woodline Partners's portfolio value rose 14% quarter-over-quarter to $6.98B.
Based on Woodline Partners's 13F filing for Q4 2021, filed 14 Feb 2022.